Evidence map›Paper›PMID 40980508›Full record

ArticleBioactive materials2025

Activatable companion theranostics for dual-modality imaging-escorted pyroptosis-propelled synergistic cancer therapy.

Yilin Wan, Yurong Liu, Weihua Wen, Ting He, Chunying Li, Guohua Wang, Lijun Jin, Meng Li, Yumeng Wu, Rong Wen and 5 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Yilin WanSchool of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yurong LiuMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Weihua WenMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Ting HeMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Chunying LiMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Guohua WangMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Lijun JinMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Meng LiMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Yumeng WuMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Rong WenMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Yifan ZhangMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Lian-Hua FuMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Jing LinMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Peng HuangMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
Daxiang CuiSchool of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Companion diagnostics (CDx) plays a pivotal role in precision medicine for cancer treatment. However, conventional CDx are often limited by their inability to provide real-time monitoring of cancer progression and therapeutic responses. Herein, we develop a dual-modality imaging-based companion theranostic (CTx) nanoplatform (LET-Cl@GOx), which integrates activatable photoacoustic (PA) and fluorescence (FL) imaging to enable the enhanced diagnostic accuracy and real-time therapeutic feedback, while demonstrating cascade-amplified photothermal/starvation synergistic therapy. The LET-Cl@GOx is designed by the assembly of glucose oxidase (GOx) with a pH-activatable near-infrared (NIR) dye (LET-Cl), enabling the turn-on of PA/FL imaging within the acidic tumor microenvironment (TME). The dynamic alterations of PA/FL imaging signals provide real-time feedback on TME acidification, enabling accurate monitoring of GOx catalysis progression and precision timing of photothermal therapy (PTT) intervention. Furthermore, the GOx-mediated tumor starvation reduces adenosine triphosphate (ATP) levels, leading to the diminished heat shock protein expression and consequently enhanced the sensitivity to PTT. Concurrently, the photothermal effect reciprocally enhances the catalytic activity of GOx, establishing a triple closed-loop system with positive feedback amplification. This multiscale-augmented synergistic therapy triggers robust pyroptosis via the Caspase-3/gasdermin E signaling pathway, demonstrating remarkable therapeutic efficacy of tumors

Indexed as

Cascade synergistic therapyCompanion theranosticsGlucose oxidasepH-responsive cyaninePyroptosis

Identifiers

PMID40980508
PMCPMC12445235

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.